LONDON and WILMINGTON, N.C., April
1, 2015 /PRNewswire/ -- Chiltern, a leading global CRO,
has ranked third among all CROs in the 2015 CenterWatch survey of
1,900 global investigative sites.
On Chiltern's high ranking, Susan
Romberg, Vice President of Global Clinical Development
noted, "First, I would like to say 'Thank You' to the all the
clinical trial investigators we are privileged to support. Chiltern
sees the benefits of specialization through having a deep
understanding of the patient experience and appreciation for
challenging site logistics. This is why we invest in building
strong partnerships with site coordinators and investigators."
The CenterWatch survey conducted between October 2014 and January
2015 measured 38 attributes of CRO-site relations from study
planning to innovation. Respondents from investigators and study
coordinators, 75% of them from North
America and Europe, rated
Chiltern in the top three for 27 of those attributes. The 2015
survey demonstrates marked improvement for CRO effectiveness
overall compared the prior survey two years ago.
Romberg went on to note the impact of internal efforts also:
"Chiltern's transparent culture, career development planning for
both technical and soft skills, empowered leadership at all levels
and a positive, supportive work environment all contribute to
employee retention that exceeds industry averages for improved site
relations."
"We've seen growing value in relationship-building among all
parties in the clinical development process and site alliances are
a significant part of that," commented Chiltern Chief Operating
Officer, Aize Smink. "I'm extremely proud of our teams for
this recognition to make site relationships a core focus, we could
not be successful without the support of all our investigators and
their staff globally."
About Chiltern:
Chiltern is a leading global CRO that
listens to client needs in order to customize solutions for the
Biopharma industry. With 33 years in service, Chiltern delivers
from three specialized business units: Chiltern Biopharma, with
deep therapeutic expertise for respiratory, anti-infectives /
vaccines, ophthalmology, dermatology and other specialty areas;
Chiltern Oncology, led by physicians, scientists and clinicians to
uniquely manage all phases of hematologic and oncologic clinical
drug development; and Chiltern Source, a world leader in tailored
relationships for FSP, resourcing and staffing solutions.
Chiltern's 2,200 engaged professionals work across 45 countries to
deliver flexible, responsive solutions that are "Designed Around
You".
Further information is available at:
http://www.chiltern.com.
For more information contact:
Nicholas Spittal
Sr. Director, Global Commercial Affairs
Chiltern International Inc.
4000 Centregreen Way, Suite 300
Cary, NC 27513
USA
Tel: +1 (919) 462 8867
Email: global.marketing@chiltern.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/chiltern-ranks-among-top-cros-in-global-survey-of-clinical-research-sites-300059276.html
SOURCE Chiltern